Back to search

Article

Electrolyte Disorders Induced by Multikinase Inhibitors Therapy for Renal Cell Carcinoma：A Large-Scale Pharmacovigilance Analysis

2023-10-09

Abstract excerpt

<h4>Objective: </h4> To provide evidence for optimization of multi-kinase inhibitors (MKIs) use in the clinic, we use the public database to describe and evaluate electrolyte disorders related to various MKIs treated for renal cell carcinoma. Methods We analyzed spontaneous reports submitted to the Food and Drug Administration Adverse Events Reporting System (FAERS) in an observational and retrospective manner. S...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
38bd457f-4be6-58a2-9a39-d5cac7116ede
DOI
10.21203/rs.3.rs-3402473/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Electrolyte Disorders Induced by Multikinase Inhibitors Therapy for Renal Cell Carcinoma：A Large-Scale Pharmacovigilance AnalysisDOI 10.21203/rs.3.rs-3402473/v1
Electrolyte disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity
Risk of acute renal failure associated with combined use of SGLT2 inhibitors and potentially nephrotoxic drugs: a pharmacovigilance study based on the FAERS databaseSemantic proximity
Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseSemantic proximity
Real-world pharmacovigilance study of voclosporin based on FAERS and VigiBaseSemantic proximity
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity
A real-world pharmacovigilance study of brentuximab vedotin based on the FAERS database from 2011 to 2024Semantic proximity
Chronic Kidney Disease: A Benefit-Risk Panorama of Baricitinib through Integrating Network Toxicology, Molecular Docking and Real-World EvidenceSemantic proximity
Tislelizumab plus lenvatinib as the first-line therapy in patients with advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, single-centre, phase 2 trial and metabolic biomarker analysisSemantic proximity
Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity
Drug-induced glucose metabolism disorders: A disproportionality analysis based on the FAERS databaseSemantic proximity
Osteonecrosis of the Jaw in Patients with Clear Cell Renal Cell Carcinoma Treated with Targeted Agents: A Case Series and Large-Scale Pharmacovigilance AnalysisSemantic proximity
Select a neighboring publication to make it the new centre.